StockData
Lexeo Therapeutics, Inc. logo

Lexeo Therapeutics, Inc. (LXEO) stock

LXEONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 7/30
$2.85−0.38 (-11.61%)

Close on Nov 17, 2026Market cap $234.24MP/E –Yield –

Lexeo Therapeutics cash

Cash and short-term investments held at the end of each period.

Lexeo Therapeutics's cash was $234.20M at Jun 30, 2026. For fiscal 2025 it was $181.77M, up 41.5% from the year before. The highest annual figure on record is $181.77M in fiscal 2025.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$181.77M+41.5%
FY2024Dec 31, 2024$128.50M+3.0%
FY2023Dec 31, 2023$124.72M+54.8%
FY2022Dec 31, 2022$80.59M-40.7%
FY2021Dec 31, 2021$135.86M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$234.20M+72.0%
Q1 FY2026Mar 31, 2026$227.60M+112.9%
Q4 FY2025Dec 31, 2025$181.77M+41.5%
Q3 FY2025Sep 30, 2025$122.76M-23.4%
Q2 FY2025Jun 30, 2025$136.14M-23.6%
Q1 FY2025Mar 31, 2025$106.90M-46.1%
Q4 FY2024Dec 31, 2024$128.50M+3.0%
Q3 FY2024Sep 30, 2024$160.27M+314.1%
Q2 FY2024Jun 30, 2024$178.23M+265.3%
Q1 FY2024Mar 31, 2024$198.31M+219.3%
Q4 FY2023Dec 31, 2023$124.72M+54.8%
Q3 FY2023Sep 30, 2023$38.70M-58.9%
Q2 FY2023Jun 30, 2023$48.79M-64.1%
Q1 FY2023Mar 31, 2023$62.12M–
Q4 FY2022Dec 31, 2022$80.59M–
Q3 FY2022Sep 30, 2022$94.15M–
Q4 FY2021Dec 31, 2021$135.86M–

More Lexeo Therapeutics figures

See a number that looks wrong?